Pharmacy

Your Article Summary

See Latest Articles

Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
Forest Laboratories, 05/13/09

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced they will be reporting additional clinical data from their Phase 2b studies for linaclotide, a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation and chronic constipation, during the 2009 Digestive Disease Week annual meeting being held in Chicago, IL from May 30 through June 2009. The presentations will include three oral and one poster presentation. Ironwood and Forest presented the initial analyses from both the IBS-C and CC studies last year.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09

 See all of Drug Trials

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09

Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09

Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09

 See all of Major Studies

Today in Stomach/GI...keeping you current

Receive free subspecialty "5-minute updates" via email

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal of Viral Hepatitis, 12/17/09

Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy
Langenbeck's Archives of Surgery, 12/17/09

The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09

 See all of Stomach/GI